HM15275 for Type 2 Diabetes

Not yet recruiting at 1 trial location

Overseen By Hyeonho Choi

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Hanmi Pharmaceutical Company Limited

Must be taking: Metformin

Must not be taking: Glucose-lowering medications

Disqualifiers: Type 1 diabetes, Cardiovascular disease, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 36 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

Are You a Good Fit for This Trial?

Inclusion Criteria

I manage my condition with diet, exercise, or stable metformin for at least 3 months.

BMI ≥25 kg/m² and ≤50 kg/m²

Body weight change <5% over the past 3 months prior to screening

Exclusion Criteria

I or my family have a history of medullary thyroid cancer or MEN2.

I have had pancreatitis or have risk factors for it.

Poor glycemic control (fasting plasma glucose >270 mg/dL)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

4 weeks

Treatment

Participants receive weekly subcutaneous injections of HM15275 or placebo for 36 weeks

36 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• HM15275

How Is the Trial Designed?

Group I: HM15275 Experimental Treatment 1 Intervention

Participants will receive HM15275 via subcutaneous (SC) injection.

Group II: Placebo of HM15275 Placebo Group 1 Intervention

Participants will receive placebo of HM15275 via subcutaneous (SC) injection.

Who Is Running the Clinical Trial?

Hanmi Pharmaceutical Company Limited

Lead Sponsor

Trials

196

Recruited

62,100+

Young Choi

Hanmi Pharmaceutical Company Limited

Chief Medical Officer since 2023

PhD in Pharmacology from Yonsei University

Jae-Hyun Park

Hanmi Pharmaceutical Company Limited

Chief Executive Officer since 2024

MD from Seoul National University